Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
CASI Pharmaceuticals ( (CASI) ) has issued an update.
CASI Pharmaceuticals has received a Termination Process Letter from Acrotech Biopharma regarding the License Agreement for the commercialization of Evomela® in China. The company disputes the termination and plans to continue distributing Evomela® during a wind-down period of up to 24 months, while actively reviewing its options in response to the situation.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a Cayman Islands incorporated company focused on the pharmaceutical industry. It primarily engages in the commercialization of pharmaceutical products, including Evomela®, in the Chinese market.
YTD Price Performance: -56.56%
Average Trading Volume: 37,642
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $41.68M
For detailed information about CASI stock, go to TipRanks’ Stock Analysis page.
